Otsuka Corporation

Equities

4768

JP3188200004

IT Services & Consulting

Market Closed - Japan Exchange 02:00:00 2024-05-24 am EDT 5-day change 1st Jan Change
2,946 JPY +0.12% Intraday chart for Otsuka Corporation +1.29% +1.34%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Otsuka Holdings' Attributable Profit Soars 26% in Fiscal Q1 MT
Otsuka to stop development of Alzheimer's disease drug RE
Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise MT
Otsuka Holdings' Attributable Profit Jumps 26% in Q1 MT
Otsuka Holdings 2.32 Billion Yen Worth of Shares As Stock Compensation MT
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy MT
Otsuka Holdings Disposes of 2.32 Billion Yen Worth of Shares as Restricted Stock Compensation MT
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia MT
Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical MT
Jefferies Adjusts Otsuka Corporation’s Price Target to 7,850 Yen From 7,100 Yen, Keeps at Buy MT
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka DJ
Otsuka Holdings' Attributable Profit Down 9.2% 2023 On Impairment Losses MT
Otsuka Holdings Lowers 2023 Profit Outlook MT
Japan's Nikkei cruises to 34-year peak, briefly breaching 38,000 range RE
Japan's Nikkei soars to 34-year high on chip shares, earnings RE
Phase 3 Trial for Otsuka's Alzheimer's-related Agitation Treatment Fails to Meet Primary Endpoint MT
Otsuka's drug for Alzheimer's disease agitation fails in late stage study RE
Otsuka Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ionis Pharmaceuticals Says Potential Angioedema Treatment Met Primary Endpoint of Phase 3 Study MT
Ionis Pharmaceuticals Signs Europe Licensing Deal With Otsuka for Donidalorsen in Hereditary Angioedema MT
Otsuka's Unit Remains as MicroPort Scientific's Thai Distributor Until 2026 MT
Otsuka Unit Buys New York-Based Provider of Women Health Products MT
Happiness Planet, Ltd. announced that it has received ¥349.995 million in funding from Otsuka Corporation CI
Jefferies: Investor Interest Shifts from Daiichi Sankyo to Chugai and Otsuka Holdings MT
US FDA approves Medtronic's blood pressure treatment device for use RE
Chart Otsuka Corporation
More charts
OTSUKA CORPORATION is a Japan-based company mainly engaged in the sale of system equipment, the installation support and maintenance services. The Company operates through two business segments. System Integration segment conducts consulting, hardware and software sales, contract software development, equipment installation and network construction. Service & Support segment provides office supply, maintenance services, as well as business support services. The Company is also involved in the car maintenance business and insurance business.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
2,946 JPY
Average target price
3,570 JPY
Spread / Average Target
+21.22%
Consensus
  1. Stock Market
  2. Equities
  3. 4768 Stock
  4. News Otsuka Corporation
  5. Sumitomo Pharma Amends Collaboration Agreement with Otsuka Pharmaceutical